Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.33 |
| ▸ | CPA1 | P15085 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | AGXT | P21549 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL894716 | 0.78 | ALDH1A1 (0.39) | IDO1LOXL2HPGDALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL893798 | 0.76 | ALDH1A1 (0.38) | IDO1LOXL2ALDH1A1POLBAGXT | |
| SCHEMBL10269762 | 0.75 | SMN1; SMN2 (0.39) | HPGDALDH1A1POLBLMNA | |
| SCHEMBL2611685 | 0.71 | HPGD (0.39) | HPGDALDH1A1POLB | |
| SCHEMBL893730 | 0.70 | BCHE (0.51) | — | |
| SCHEMBL2298642 | 0.62 | STAT3 (0.43) | — | |
| SCHEMBL2098314 | 0.62 | KDM4E (0.56) | — | |
| SCHEMBL5822005 | 0.59 | IDO1 (0.34) | IDO1LOXL2TAAR1AGXT | |
| SCHEMBL23461 | 0.58 | — | — | |
| SCHEMBL15734925 | 0.57 | IDO1 (0.46) | IDO1LOXL2TAAR1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083470-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2012-04-05 | — | — | US | disclosed |
| US-8067395-B2 | Inhibitors of tyrosine kinases and uses thereof | PHARMACYCLICS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100035841-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-7625880-B2 | Inhibitors of tyrosine kinases and uses thereof | PHARMACYCLICS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080039426-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| WO-2006086609-A2 | INHIBITORS OF TRYPTASE | AXYS PHARMACEUTICALS, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035841-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | LCK, ABL1, SRC | IDO1 1595/4885LOXL2 777/4885HPGD 1544/4885 |
| US-20120083470-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | LCK, ABL1, SRC | IDO1 1595/4885LOXL2 777/4885HPGD 1544/4885 |
| US-20080039426-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | LCK, ABL1, SRC | IDO1 1595/4885LOXL2 777/4885HPGD 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.